I haven’t been around to view the chat much rece

I haven’t been around to view the chat much recently. It’s been awhile. Thanks for the updates and I appreciate it. I missed the handing in of the 5 sections and an added 6th. Thanks again!

I am happy to see it because my concern was the data for safety wasn’t up to snuff because of Amerex. To see that all sections were handed in is in of its own self a great thing to me. I feel that safety must of been met in order to make this possible. This alone to me is huge. After all… we all thought it was the safety that made us better than the competition and we now have competition on every use of Leronlimab we have trialed.

We won’t be the first to market now and missed that boat. But… if we can prove to be safer with little to no side effects then we can come from behind and take a market share or at least a nice share on every successful approved use. Hopefully we are still the multi platform drug we always hoped we are. It’s good that we are now focused with new leadership pushing the right buttons to make us whole and successful. Hoping for all the stars to line up and do us all good!